Active substance
Lanthanum carbonate
- US FDA 7
- US price lines 2
- NHS prices 5
- Safety 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| FOSRENOL | EQ 500MG BASE; EQ 750MG BASE; EQ 1GM BASE | tablet, chewable · oral | TAKEDA PHARMS USA | Prescription | 26 Oct 2004 |
| FOSRENOL | EQ 750MG BASE; EQ 1GM BASE | powder · oral | TAKEDA PHARMS USA | Prescription | 24 Sep 2014 |
| LANTHANUM CARBONATE | EQ 500MG BASE; EQ 750MG BASE; EQ 1GM BASE | tablet, chewable · oral | NATCO PHARMA LTD | Prescription | 11 Aug 2017 |
| LANTHANUM CARBONATE | EQ 500MG BASE; EQ 750MG BASE; EQ 1GM BASE | tablet, chewable · oral | INVAGEN PHARMS | Prescription | 24 Jan 2022 |
| LANTHANUM CARBONATE | EQ 500MG BASE; EQ 750MG BASE; EQ 1GM BASE | tablet, chewable · oral | BARR | Prescription | 27 Jan 2022 |
| LANTHANUM CARBONATE | EQ 500MG BASE; EQ 750MG BASE; EQ 1GM BASE | tablet, chewable · oral | ALKEM LABS LTD | Prescription | 13 Mar 2025 |
| FOSRENOL | EQ 250MG BASE | tablet, chewable · oral | TAKEDA PHARMS USA | Discontinued | 26 Oct 2004 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LANTHANUM CARB 1,000 MG TB CHW | $3.15131 | per EA | 23 Sep 2026 |
| US NADAC | LANTHANUM CARB 500 MG TAB CHEW | $3.18293 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Lanthanum carbonate 1g chewable tablets | £193.59 | 90 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lanthanum carbonate 1g oral powder sachets | £193.59 | 90 sachet | 1 Oct 2026 |
| NHS Drug Tariff | Lanthanum carbonate 500mg chewable tablets | £124.06 | 90 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lanthanum carbonate 750mg chewable tablets | £182.60 | 90 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Lanthanum carbonate 750mg oral powder sachets | £182.60 | 90 sachet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 29 Aug 2024 FOSRENOL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 29 Aug 2024 FOSRENOL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.